Taken up the entitlement?, page-255

Hi @Leo65

as a non-biomedical scientist, I was very interested to read about your belief in the science.

At this pivotal moment for MSB, with such a focus on analytical process, there's such a dearth of comment from holders on HC:MSB about, for example, relative potency, or comparability studies, or the FDA's position on recognition of ICH Q2 (R2) that it would be good to read some new and informed points of view.

Personally, I'm particularly interested in whether, from public statements etc, you'd consider MSB might reasonably be thought at this time to have a well-characterised in-house material or whether we are going to have to rely on FDA finally getting round to endorsing a national/ international reference standard.

I'm guessing from your investment what your answer might be. And, yes, we have matched investments.

Cheers
GLTAH